ELISIDEPSIN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C75H124N14O16
Molecular Weight	1477.8742
Optical Activity	UNSPECIFIED
Defined Stereocenters	17 / 17
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@](NC(=O)[C@H](NC(=O)CC[C@@H](C)CC)C(C)C)([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N1CCC[C@]1([H])C(=O)N[C@@H](CCCN)C(=O)N[C@]([H])([C@@H](C)CC)C(=O)N[C@@H]2[C@@H](C)OC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](NC(=O)[C@]([H])(NC2=O)[C@@H](C)CC)C(C)C)=C\C)C(C)C

InChI

InChIKey=ZNVCPJPCKSJWDH-UCTDCHLSSA-N

InChI=1S/C75H124N14O16/c1-20-43(15)33-34-53(91)80-54(38(5)6)68(97)87-61(46(18)90)72(101)82-56(40(9)10)69(98)83-57(41(11)12)74(103)89-36-28-32-52(89)66(95)78-50(31-27-35-76)64(93)85-59(44(16)21-2)71(100)88-62-47(19)105-75(104)58(42(13)14)84-63(92)49(23-4)77-65(94)51(37-48-29-25-24-26-30-48)79-67(96)55(39(7)8)81-70(99)60(45(17)22-3)86-73(62)102/h23-26,29-30,38-47,50-52,54-62,90H,20-22,27-28,31-37,76H2,1-19H3,(H,77,94)(H,78,95)(H,79,96)(H,80,91)(H,81,99)(H,82,101)(H,83,98)(H,84,92)(H,85,93)(H,86,102)(H,87,97)(H,88,100)/b49-23-/t43-,44-,45-,46+,47+,50-,51-,52+,54+,55+,56-,57+,58-,59+,60+,61-,62+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C75H124N14O16
Molecular Weight	1477.8742
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	17 / 17
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1497635&p_IsPs=N | https://www.ncbi.nlm.nih.gov/pubmed/21556352 | https://adisinsight.springer.com/drugs/800023321

Elisidepsin (Irvalec®, PM02734) is a depsipeptide produced by chemical synthesis and chosen for development as an antineoplastic agent based on its in vitro activity against human solid tumor cell lines, in vivo activity in hollow fibers and xenografted human tumors, as well as its acceptable preclinical toxicology profile. Elisidepsin causes a typical necrotic cell death and induces profound alterations in tumor cell morphology. Elisidepsin inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. PharmaMar was developing elisidepsin for the treatment of cancer. However, development of the compound has been suspended.

Originator

Approval Year

PubMed

Title	Date	PubMed
Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.	2013-03-20	23519149
Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells.	2011-04-27	21556352

Sample Use Guides

In Vitro Use Guide

Elisidepsin showed potent and broad cytotoxic effects in a cancer cell line panel, being active at concentrations ranging from 0.4 to 2 μM that may be relevant for clinical settings.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:56:33 GMT 2025` Edited by `admin` on `Mon Mar 31 20:56:33 GMT 2025`
Record UNII	0FWR494EC9
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

elisidepsin [INN]

Preferred Name

English

ELISIDEPSIN

Official Name

English

ELISIDEPSIN [MI]

Common Name

English

L-VALINE, N-((4S)-4-METHYL-1-OXOHEXYL)-D-VALYL-L-THREONYL-L-VALYL-D-VALYL-D-PROLYL-L-ORNITHYL-D-ALLOISOLEUCYL-D-ALLOTHREONYL-D-ALLOISOLEUCYL-D-VALYL-L-PHENYLALANYL-(2Z)-2-AMINO-2-BUTENOYL-, (13-8)-LACTONE

Common Name

English

N-((4S)-4-METHYL-1-OXOHEXYL)-D-VALYL-L-THREONYL-L-VALYL-D-VALYL-D-PROLYL-L-ORNITHYL-D-ALLOISOLEUCYL-D-ALLOTHREONYL-D-ALLOISOLEUCYL-D-VALYL-L-PHENYLALANYL-(2Z)-2-AMINO-2-BUTENONYL-L-VALINE (13->8)-LACTONE

Common Name

English

1-(N-((4S)-4-METHYL-1-OXOHEXYL)-D-VALINE)KAHALALIDE F

Common Name

English

Elisidepsin [WHO-DD]

Common Name

English

ISOKAHALALIDE F

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1976